

Eric Delabesse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2839462/publications.pdf>

Version: 2024-02-01

155
papers

16,880
citations

50276

46
h-index

14759

127
g-index

157
all docs

157
docs citations

157
times ranked

18038
citing authors

#	ARTICLE	IF	CITATIONS
1	The <i>CADM1</i> tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11. <i>Blood Advances</i> , 2022, 6, 386-398.	5.2	3
2	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2022, 36, 913-922.	7.2	23
3	Genomic landscape of hyperleukocytic acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 4.	6.2	7
4	Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study. <i>Leukemia and Lymphoma</i> , 2022, 63, 1398-1406.	1.3	3
5	Prognostic impact of <i>DDX41</i> germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. <i>Blood</i> , 2022, 140, 756-768.	1.4	48
6	A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	4
7	Germline <i>PAX5</i> mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1424-1428.	1.4	32
8	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021, 35, 1291-1300.	7.2	5
9	Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006 intermediate-risk trial. <i>European Journal of Haematology</i> , 2021, 107, 111-121.	2.2	4
10	GATA2 deficiency phenotype associated with tandem duplication of <i>GATA2</i> and overexpression of <i>GATA2-AS1</i> . <i>Blood Advances</i> , 2021, 5, 5631-5635.	5.2	5
11	Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 180.	6.2	2
12	Outcome of relapsed/refractory AML patients with IDH1 ^{R132} mutations in real life before the era of IDH1 inhibitors. <i>Leukemia and Lymphoma</i> , 2020, 61, 473-476.	1.3	2
13	Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. <i>PLoS ONE</i> , 2020, 15, e0238795.	2.5	12
14	Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. <i>Blood Advances</i> , 2020, 4, 3840-3849.	5.2	13
15	Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. <i>Cancers</i> , 2020, 12, 2044.	3.7	8
16	CD34+CD38 [~] CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. <i>Cancers</i> , 2020, 12, 1174.	3.7	7
17	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020, 136, 698-714.	1.4	28
18	More than ten percent of relapses occur after five years in AML patients with NPM1 mutation. <i>Leukemia and Lymphoma</i> , 2020, 61, 1226-1229.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study. <i>Cancers</i> , 2020, 12, 773.	3.7	11
20	Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 3307-3318.	7.0	28
21	Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience. <i>Cancer Medicine</i> , 2019, 8, 3846-3854.	2.8	14
22	Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. <i>Leukemia Research</i> , 2019, 81, 82-87.	0.8	11
23	B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL. <i>Frontiers in Oncology</i> , 2019, 9, 1374.	2.8	28
24	The impact of chronic myeloid leukemia on employment: the French prospective study. <i>Annals of Hematology</i> , 2019, 98, 615-623.	1.8	4
25	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 102, 131-142.	2.2	57
26	PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. <i>Blood</i> , 2019, 133, 280-284.	1.4	48
27	A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2489-2492.	1.3	9
28	Dexamethasone in hyperleukocytic acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 988-998.	3.5	49
29	PAX5A and PAX5B isoforms are both efficient to drive B cell differentiation. <i>Oncotarget</i> , 2018, 9, 32841-32854.	1.8	4
30	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3203-3210.	1.6	32
31	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2514-2523.	1.6	99
32	PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10357-10362.	7.1	20
33	Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis. <i>Leukemia Research</i> , 2018, 75, 7-10.	0.8	1
34	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. <i>Haematologica</i> , 2018, 103, 1278-1287.	3.5	129
35	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. <i>Leukemia</i> , 2018, 32, 2066-2069.	7.2	4
36	Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 2806-2806.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine. Blood, 2018, 132, 1467-1467.	1.4	0
38	More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission. Blood, 2018, 132, 2802-2802.	1.4	0
39	TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine. Blood, 2018, 132, 2745-2745.	1.4	0
40	Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. Leukemia Research, 2017, 61, 62-67.	0.8	33
41	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood, 2017, 130, 1832-1844.	1.4	66
42	Improved outcome for AML patients over the years 2000â€“2014. Blood Cancer Journal, 2017, 7, 635.	6.2	63
43	Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. Haematologica, 2017, 102, 1718-1726.	3.5	32
44	Major prognostic value of complex karyotype in addition to <i>TP53</i> and <i>IGHV</i> mutational status in firstâ€“line chronic lymphocytic leukemia. Hematological Oncology, 2017, 35, 664-670.	1.7	32
45	Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia. Blood Advances, 2017, 1, 1760-1772.	5.2	41
46	Impact of obesity in favorableâ€“risk <i>AML</i> patients receiving intensive chemotherapy. American Journal of Hematology, 2016, 91, 193-198.	4.1	22
47	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood, 2016, 127, 882-892.	1.4	108
48	CHK1 as a therapeutic target to bypass chemoresistance in AML. Science Signaling, 2016, 9, ra90.	3.6	73
49	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 483-497.	8.5	68
50	Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice. Blood, 2016, 128, 1718-1718.	1.4	2
51	Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia. Blood, 2016, 128, 2892-2892.	1.4	1
52	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. Blood, 2016, 128, 762-762.	1.4	13
53	Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Oncotarget, 2016, 7, 73769-73780.	1.8	30
54	Abstract A27: Long noncoding RNA expression in cytogenetically normal acute myeloid leukemia identifies a distinct signature associated with NPM1 mutations. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
55	Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases. Blood, 2016, 128, 2861-2861.	1.4	0
56	Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia. Blood, 2016, 128, 1636-1636.	1.4	2
57	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood, 2015, 125, 13-21.	1.4	168
58	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica, 2015, 100, 780-785.	3.5	42
59	A novel method for room temperature distribution and conservation of RNA and DNA reference materials for guaranteeing performance of molecular diagnostics in onco-hematology: A GBMHM study. Clinical Biochemistry, 2015, 48, 982-987.	1.9	5
60	Antileukemic Activity of 2-Deoxy- α -D-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. Molecular Cancer Therapeutics, 2015, 14, 2364-2373.	4.1	52
61	Comparison of 60 or 90 mg/m ² of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. American Journal of Hematology, 2015, 90, E29-30.	4.1	19
62	The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations. Blood, 2015, 126, 2542-2542.	1.4	4
63	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget, 2015, 6, 8388-8396.	1.8	69
64	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget, 2015, 6, 38061-38078.	1.8	20
65	Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML. Blood, 2015, 126, 90-90.	1.4	0
66	GATA2, a new oncogene of sporadic and familial acute myeloid leukemias. Hematologie, 2014, 20, 153-160.	0.0	0
67	Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network. American Journal of Hematology, 2014, 89, E244-52.	4.1	59
68	Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations. European Journal of Haematology, 2014, 93, 533-536.	2.2	12
69	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood, 2014, 123, 3739-3749.	1.4	281
70	Declined Presentation. Experimental Hematology, 2014, 42, S27.	0.4	0
71	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. Haematologica, 2014, 99, e185-e187.	3.5	27
72	Abstract 2678: All-trans-retinoic acid as a new therapeutic approach to target isocitrate dehydrogenase mutations in acute myeloid leukemia. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
73	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. <i>Blood</i> , 2013, 121, 2213-2223.	1.4	313
74	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. <i>Blood</i> , 2013, 121, 822-829.	1.4	189
75	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. <i>Blood</i> , 2013, 121, 2618-2626.	1.4	100
76	Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. <i>Haematologica</i> , 2013, 98, 1414-1420.	3.5	46
77	The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. <i>Haematologica</i> , 2013, 98, 1711-1717.	3.5	41
78	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	3.5	50
79	Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1651-1651.	1.4	2
80	Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias. <i>Blood</i> , 2013, 122, 2681-2681.	1.4	1
81	T315I-Mutated BCR-ABL Induces a Distinct and Specific Molecular Signature With High Expression Of Zinc Finger (ZNF) Transcription Factors. <i>Blood</i> , 2013, 122, 4899-4899.	1.4	0
82	Genetic polymorphisms in <i>ARID5B</i> , <i>CEBPE</i> , <i>IKZF1</i> and <i>CDKN2A</i> in relation with risk of acute lymphoblastic leukaemia in adults: a <i>GROUP R</i> research on <i>Acute Lymphoblastic Leukaemia</i> (GRAALL) study. <i>British Journal of Haematology</i> , 2012, 159, 599-613.	2.5	18
83	PICALM-MLLT10 acute myeloid leukemia: A French cohort of 18 patients. <i>Leukemia Research</i> , 2012, 36, 1365-1369.	0.8	36
84	TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia. <i>PLoS ONE</i> , 2012, 7, e31605.	2.5	70
85	Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.. <i>Blood</i> , 2012, 120, 2879-2879.	1.4	6
86	A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). <i>Nature Genetics</i> , 2011, 43, 673-678.	21.4	244
87	Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. <i>Blood</i> , 2011, 117, 5719-5722.	1.4	44
88	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. <i>Haematologica</i> , 2011, 96, 1792-1798.	3.5	164
89	TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. <i>Haematologica</i> , 2011, 96, 1059-1063.	3.5	34
90	Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R ^{3c} -deficient mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 384-395.	8.2	336

#	ARTICLE	IF	CITATIONS
91	International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. Blood, 2011, 118, 2535-2535.	1.4	4
92	Efficacy of Frontline 5-Azacytidine in Older AML Patient Unfit for Chemotherapy. Blood, 2011, 118, 2614-2614.	1.4	4
93	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget, 2011, 2, 850-861.	1.8	29
94	Abstract 3130: The short form of the receptor tyrosine kinase Ron is expressed in acute myeloid leukemia, regulated by methylation and sensitizes leukemic cells to c-Met inhibitors. , 2011, , .		0
95	What Is New? An Update of the MLL Recombinome Including the Three Novel Partner Genes ABI2, PDS5A, and TOP3A. Blood, 2011, 118, 1351-1351.	1.4	0
96	Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. Blood, 2011, 118, 410-410.	1.4	0
97	Uterine chloroma, aortic thrombus and CALM/AF10 acute myeloid leukemia. Leukemia Research, 2010, 34, e88-e90.	0.8	5
98	Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients. PLoS ONE, 2010, 5, e8893.	2.5	27
99	Epidermal Growth Factor Receptor/ β -Catenin/T-Cell Factor 4/Matrix Metalloproteinase 1: A New Pathway for Regulating Keratinocyte Invasiveness after UVA Irradiation. Cancer Research, 2009, 69, 3291-3299.	0.9	25
100	Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome-“Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study. Journal of Clinical Oncology, 2009, 27, 911-918.	1.6	506
101	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291.	1.4	264
102	Long-Term Results of the Imatinib GRAAPH-2003 Study in Newly-Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia... Blood, 2009, 114, 3080-3080.	1.4	7
103	Primary cutaneous Epstein-Barr virus-“related lymphoproliferative disorders in 4 immunosuppressed children. Journal of the American Academy of Dermatology, 2008, 58, 74-80.	1.2	27
104	Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. Journal of Clinical Investigation, 2008, 118, 3132-3142.	8.2	1,531
105	Transcriptional activation of the cardiac homeobox gene CSX1/NKX2-5 in a B-cell chronic lymphoproliferative disorder. Haematologica, 2008, 93, 1081-1085.	3.5	7
106	Primary Leptomeningeal ALK+ Lymphoma in a 13-year-old Child. Journal of Pediatric Hematology/Oncology, 2008, 30, 963-967.	0.6	25
107	Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-“positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood, 2007, 109, 1408-1413.	1.4	300
108	Detection of the MPL W515L mutation in bone marrow core biopsy specimens with essential thrombocythemia using the TaqMan assay. Human Pathology, 2007, 38, 1581-1582.	2.0	3

#	ARTICLE	IF	CITATIONS
109	Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 2202-2204.	1.4	114
110	Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4-MLL fusion allele. <i>Leukemia</i> , 2007, 21, 1232-1238.	7.2	40
111	The CALM-AF10 fusion is a rare event in acute megakaryoblastic leukemia. <i>Leukemia</i> , 2007, 21, 2568-2569.	7.2	1
112	A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. <i>Cancer Genetics and Cytogenetics</i> , 2007, 173, 17-22.	1.0	9
113	Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. <i>Journal of Clinical Investigation</i> , 2007, 117, 2225-2232.	8.2	221
114	PAX5 Mutations Occur Frequently in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Is Significantly Associated with BCR-ABL1 Fusion Gene.. <i>Blood</i> , 2007, 110, 2806-2806.	1.4	1
115	Prognostic Significance of CD20 Expression in Adult B-Cell Precursor Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007, 110, 2829-2829.	1.4	2
116	Novel Spliced MLL Fusions Have Been Identified Involving the MLL Partner Genes ELL, EPS15, MLLT3, and SEPT5.. <i>Blood</i> , 2007, 110, 978-978.	1.4	0
117	Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17). <i>Blood</i> , 2006, 108, 3484-3493.	1.4	34
118	The MLL recombinome of acute leukemias. <i>Leukemia</i> , 2006, 20, 777-784.	7.2	196
119	Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Leukemia</i> , 2006, 20, 793-799.	7.2	22
120	HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocation. <i>Leukemia</i> , 2006, 20, 1184-1187.	7.2	31
121	Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. <i>Leukemia</i> , 2006, 20, 1526-1532.	7.2	106
122	Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. <i>Leukemia</i> , 2006, 20, 2178-2181.	7.2	9
123	Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 174-175.	1.0	7
124	Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. <i>Cancer Cell</i> , 2006, 10, 363-374.	16.8	119
125	Acute monocytic leukemia with coexpression of minorBCR-ABL1 andPICALM-MLLT10 fusion genes along with overexpression ofHOXA9. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 575-582.	2.8	4
126	DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. <i>Leukemia</i> , 2005, 19, 1338-1344.	7.2	47

#	ARTICLE	IF	CITATIONS
127	CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. <i>Leukemia</i> , 2005, 19, 1948-1957.	7.2	110
128	IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner. <i>Leukemia</i> , 2005, 19, 2337-2338.	7.2	14
129	Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells. <i>International Journal of Cancer</i> , 2005, 115, 511-518.	5.1	31
130	AF4p12, a Human Homologue to the furry Gene of Drosophila, as a Novel MLL Fusion Partner. <i>Cancer Research</i> , 2005, 65, 6521-6525.	0.9	20
131	Transcriptional Regulation of the SCL Locus: Identification of an Enhancer That Targets the Primitive Erythroid Lineage In Vivo. <i>Molecular and Cellular Biology</i> , 2005, 25, 5215-5225.	2.3	55
132	Characterization of the imprinted polycomb gene <i>L3MBTL</i> , a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. <i>British Journal of Haematology</i> , 2004, 127, 509-518.	2.5	36
133	Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. <i>Blood</i> , 2004, 104, 4173-4180.	1.4	94
134	Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.. <i>Blood</i> , 2004, 104, 2741-2741.	1.4	6
135	Absence of SCL mutations in myeloid malignancies. <i>British Journal of Haematology</i> , 2003, 120, 482-483.	2.5	0
136	Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) " a Europe against cancer program. <i>Leukemia</i> , 2003, 17, 2474-2486.	7.2	806
137	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. <i>Leukemia</i> , 2003, 17, 2257-2317.	7.2	2,788
138	<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. <i>Science</i> , 2003, 302, 415-419.	12.6	3,264
139	FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. <i>Blood</i> , 2003, 102, 2198-2204.	1.4	90
140	Analysis of TCR, pTÎ±, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. <i>Blood</i> , 2003, 101, 2693-2703.	1.4	152
141	CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCR-Î± lineage. <i>Blood</i> , 2003, 102, 1000-1006.	1.4	148
142	Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. <i>Leukemia</i> , 2002, 16, 587-593.	7.2	144
143	Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. <i>Blood</i> , 2002, 99, 4547-4553.	1.4	74
144	Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL?. <i>Leukemia</i> , 2002, 16, 2134-2141.	7.2	48

#	ARTICLE	IF	CITATIONS
145	Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. EMBO Journal, 2002, 21, 3039-3050.	7.8	194
146	The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. Blood, 2000, 96, 2254-2261.	1.4	63
147	Association of a Duodenal Follicular Lymphoma and Hereditary Nonpolyposis Colorectal Cancer. Modern Pathology, 2000, 13, 586-590.	5.5	17
148	Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet, The, 2000, 356, 203-208.	13.7	698
149	Virological and Molecular Characterisation of a New B Lymphoid Cell Line, Established from an AIDS Patient with Primary Effusion Lymphoma, Harbours Both KSHV/HHV8 and EBV Viruses. Leukemia and Lymphoma, 2000, 38, 401-409.	1.3	30
150	Is Complicated Celiac Disease or Refractory Sprue an Intestinal Intra-Epithelial Cryptic T-Cell Lymphoma?. Blood, 1999, 93, 3154-3155.	1.4	21
151	Deregulated expression of the TAL1 gene by t(1;5)(p32;q31) in patient with T-cell acute lymphoblastic leukemia. , 1998, 23, 36-43.		12
152	Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. Genes Chromosomes and Cancer, 1998, 23, 220-226.	2.8	20
153	TAL1 expression does not occur in the majority of T-ALL blasts. British Journal of Haematology, 1998, 102, 449-457.	2.5	18
154	Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology, 1998, 114, 471-481.	1.3	368
155	Simultaneous SIL-TAL1 RT-PCR detection of all tal1 deletions and identification of novel tal1 variants. British Journal of Haematology, 1997, 99, 901-907.	2.5	34